Compare ZKH & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZKH | AURA |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.5M | 396.8M |
| IPO Year | 2023 | 2021 |
| Metric | ZKH | AURA |
|---|---|---|
| Price | $3.20 | $6.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $20.33 |
| AVG Volume (30 Days) | ★ 211.9K | 197.8K |
| Earning Date | 11-20-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,236,195,501.00 | N/A |
| Revenue This Year | $2.44 | N/A |
| Revenue Next Year | $9.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.50 | $4.35 |
| 52 Week High | $4.03 | $9.14 |
| Indicator | ZKH | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 60.80 |
| Support Level | $2.93 | $5.89 |
| Resistance Level | $3.49 | $6.53 |
| Average True Range (ATR) | 0.18 | 0.33 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 48.67 | 86.21 |
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.